Corvus Pharmaceuticals Inc.

5.36
0.14 (2.68%)
Jan 22, 2025, 3:45 PM - Market open
2.68%
Bid 5.34
Market Cap 344.10M
Revenue (ttm) 236.99K
Net Income (ttm) -54.75M
EPS (ttm) -0.99
PE Ratio (ttm) -5.41
Forward PE -18.1
Analyst Buy
Ask 5.37
Volume 422,322
Avg. Volume (20D) 1,159,655
Open 5.27
Previous Close 5.22
Day's Range 5.26 - 5.59
52-Week Range 1.30 - 10.00
Beta 1.04

About CRVS

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat pa...

Industry Biotechnology
Sector Healthcare
IPO Date Mar 23, 2016
Employees 28
Stock Exchange NASDAQ
Ticker Symbol CRVS

Analyst Forecast

According to 5 analyst ratings, the average rating for CRVS stock is "Buy." The 12-month stock price forecast is $12.5, which is an increase of 133.43% from the latest price.

Buy 80.00%
Hold 20.00%
Sell 0.00%
Stock Forecasts
1 month ago
-36.4%
Corvus Pharmaceuticals shares are trading lower. T... Unlock content with Pro Subscription
1 month ago
+7.1%
Corvus Pharmaceuticals shares are trading higher after the company announced it will report on December 18 interim data from its Phase 1 clinical trial evaluating Soquelitinib in patients with moderate to severe atopic dermatitis.